 CAMBRIDGE, Mass.--BUSINESS WIRE--Syros Pharmaceuticals NASDAQ: SYRS, a leader in the development of medicines that control the expression of genes, announced today that it has priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of 14.00 per share, which would result in gross proceeds of approximately 75.6 million, before underwriting discounts and commissions. The proceeds of the offering are expected to be used to fund the development of 